Larvol Delta - Argo-Biopharmaceuticalannounced-the-rst-patient-has-been-dosed-in-multiple-Phase-II-studies-of-BW40202-an-investigational-siRNA-therapy-targeting-complement-factor-B-CFB

BW-40202 - Argo Biopharma

https://www.prnewswire.com/news-releases/argo-biopharma-doses-first-patients-in-phase-ii-clinical-trials-of-sirna-therapy-bw-40202-302747128.html

Apr 20, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next